Novo Nordisk A/S Sponsored ADR (NVO)
Why Novo Nordisk (NVO) is a Top Value Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
UK Pharma Industry Trade Association Restores Wegovy/Ozempic Maker Novo Nordisk's Membership After 2 Years Of Suspension
On Monday, Novo Nordisk A/S NVO returned to full membership of the Association of the British Pharmaceutical Industry (ABPI) following extensive audits of the Wegovy maker's compliance procedures and governance by the Prescription Medicines Code of Practice Authority (PMCPA).
NVO vs. LLY: Which Stock Is the Better Value Option?
Investors interested in stocks from the Large Cap Pharmaceuticals sector have probably already heard of Novo Nordisk (NVO) and Eli Lilly (LLY). But which of these two stocks is more attractive to value investors?
Novo Nordisk membership in UK pharma body restored after suspension
Danish company Novo Nordisk's membership in a UK pharmaceutical industry body has been restored after a two-year suspension for breaching a national drugmakers practice code.
Why Novo Nordisk (NVO) is a Top Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Focus List.
Here is What to Know Beyond Why Novo Nordisk A/S (NVO) is a Trending Stock
Zacks.com users have recently been watching Novo Nordisk (NVO) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Novo Nordisk: Stock Plunges, But It May Be Time To Load Up
Defensive healthcare stocks have been a haven, but Novo Nordisk's recent setbacks have compounded investor confidence in the stock. Novo Nordisk faces formidable challenges from Eli Lilly and new rivals, but its first-mover advantage and expanded manufacturing capacity remain strong. NVO's valuation has dropped significantly after the stock collapsed more than 40% over the past year.
NVO Stock Slips 4% as Roche Inks Obesity Drug Deal With Zealand
With Roche's latest deal, a new contender enters the obesity space, which could threaten NVO and LLY's dominance in the market.
Novo Nordisk sell-off is completely overdone, says Mizuho's Jared Holz
Jared Holz, Mizuho, joins 'Fast Money' to talk Novo Nordisk stock nearing two-year lows.
How a Novo Nordisk Foundation-funded project sparked ultra-processed food fight
The Novo Nordisk Foundation and University of Copenhagen researchers have backtracked over a project to redefine how the world understands ultra-processed foods, after more than 90 independent food scientists warned of confusion and conflicts of interest.
NVO Stock Down 9% as CagriSema Misses Target in Second Obesity Study
Novo Nordisk stock slumps as the 15.7% weight loss achieved with its next-gen obesity candidate, CagriSema, in the second phase III study, missing the guidance of 25%.
Healthy Returns: Wegovy is linked to an increased risk of hair loss, study suggests
Novo Nordisk's weight loss drug Wegovy is linked to an increased risk of hair loss, a study suggests. Meanwhile, Dexcom received a warning letter from FDA.
